Introduction
============

Age-related macular degeneration (AMD) is an ocular disease that involves the posterior aspect of the retina called the macula. The macula facilitates central vision and permits high-resolution visual acuity due to its dense concentration of cone photoreceptors ([@b22-cia-3-473]). There is an early and late stage of AMD. In the early stage, there is formation of large drusen and pigmentary abnormalities ([@b22-cia-3-473]). The late stage is divided into two groups: nonexudative or "dry" form and an exudative/neovascular or "wet" form. The nonexudative form is characterized by atrophic changes in the macula and clinically, has a slower deterioration and better preservation of visual acuity than exudative AMD ([@b22-cia-3-473]). Exudative AMD involves choroidal neovascularization, which is the formation of new abnormal blood vessels in the choriocapillaries through Bruch's membrane ([Figure 1](#f1-cia-3-473){ref-type="fig"}). These vessels have a greater tendency of leakage and bleeding into the macula, ultimately leading to irreversible damage to the photoreceptors if left untreated ([@b22-cia-3-473]). Hence, the exudative form accounts for most cases of significant visual loss from AMD ([@b12-cia-3-473]).

AMD is the leading cause of visual deterioration and legal blindness in patients over 60 years of age ([@b44-cia-3-473]). The loss of central vision and high-resolution visual acuity from untreated AMD can lead to an irreversible loss of reading, facial recognition, and driving ([@b22-cia-3-473]). Changes in the macula occur over time and occur more often in the elderly. The prevalence of AMD among 40- to 49-year-olds is 2.1%, which increases dramatically to 35% among those over 80 years of age ([@b58-cia-3-473]). Additionally, the disease can progress with approximately 10%--20% of patients with nonexudative AMD progressing to the exudative form if untreated ([@b42-cia-3-473]). Furthermore, almost 40% of patients have bilateral disease ([@b83-cia-3-473]). The risk factors for AMD include ethnicity, gender, hypertension, genetics, diet, and sunlight exposure. Studies have shown that the late stages of AMD are more common in whites than in other ethnic groups and that women are affected more than men ([@b42-cia-3-473]). Nevertheless, the strongest, most consistent risk factors are smoking and age ([@b42-cia-3-473]).

Although aging will not inevitably lead to AMD development, there are changes with age that can predispose the eye to development of AMD. Primary senescence of retinal pigment epithelial cells and Bruch's membrane can lead to accumulation of metabolic debris and drusen. Furthermore, primary abnormalities in ocular perfusion worsen with age, secondarily causing dysfunction of the retinal pigment epithelial cells, predisposing eyes to AMD. These anatomical changes together with an individual's genetic make-up and environmental risk factors set the stage for the development of AMD ([@b12-cia-3-473]).

In this report, we focus on the role that aging plays in the pathogenesis of AMD. We start from a structural approach with alterations in the retinal pigment epithelium-Bruch's membrane-choriocapillaris complex. Then we focus on the vascular changes with an attention to ocular blood flow alterations that correlate with AMD lesion development. Finally, we discuss the role of genetics in development of AMD.

Structural changes with age and in AMD
======================================

The outer retina is made up of the retinal pigment epithelium and photoreceptors. The retinal pigment epithelial cells form the outer blood-retinal barrier to facilitate selective transport between the choroidal blood vessels and the outer retina ([@b69-cia-3-473]). Therefore, they play a major role in rod and cone photoreceptor integrity. The retinal pigment epithelium is a phagocytic system that is essential to the renewal of photoreceptors ([@b16-cia-3-473]). When the tips (or outer segments) of photoreceptors are shed, retinal pigment epithelial cells have been shown to engulf and to degrade its components ([@b16-cia-3-473]). [@b8-cia-3-473] speculate that the retinal pigment epithelium then transports the engulfed cytoplasmic material through Bruch's membrane into the choriocapillaries.

Age-related processes that occur in the retinal pigment epithelium-Bruch's membrane-choriocapillaris complex can precede the development of AMD ([@b51-cia-3-473]). With advancing age, retinal pigment epithelial cells undergo an increase in pleomorphism, a decrease in the concentration of cells in the posterior pole, and decreased melanin content ([@b69-cia-3-473]). Senescent retinal pigment epithelial cells accumulate metabolic debris from remnants of incomplete degradation of phagocytized rod and cone membranes ([@b12-cia-3-473]). Fatty acids from the outer segment receptors are degraded by lipid peroxidation, a process that increases with age in the macula ([@b89-cia-3-473]). Susuki et al (2007) found oxidized phospholipids present in photoreceptors and retinal pigment epithelial cells in the macula of the normal eyes, with increased quantities with advanced age. Metabolic debris includes lipofuscin, an undegradable byproduct of outer segment photoreceptor metabolism, which increases in concentration within retinal pigment epithelial cell cytoplasm over time ([@b21-cia-3-473]). It is believed that lipofuscin and fatty acids are continuously exposed to light and high oxygen tension, which initiates the production of reactive oxygen species ([@b89-cia-3-473]). It is further postulated that these cause oxidative damage to the cellular mitochondria and to mitochondrial DNA, which is most susceptible to this oxidative stress ([@b51-cia-3-473]). Injury to the mitochondria leads to a reduction in energy production, compromises cellular and physiologic functioning, and can subsequently signal apoptosis in retinal pigment epithelial cells ([@b51-cia-3-473]; [@b89-cia-3-473]). Increased apoptosis eventually causes a decreased number of retinal pigment epithelial cells ([@b9-cia-3-473]). In order to counteract the formation of reactive oxygen species, retinal pigment epithelial cells contain anti-oxidants, which decrease with age ([@b51-cia-3-473]). The Age-Related Eye Disease Study (AREDS) has demonstrated that the administration of anti-oxidants, such as vitamins B, C, E, and zinc, significantly slows the rate of progression from high-risk nonexudative AMD to exudative AMD ([@b2-cia-3-473]).

Retinal pigment epithelial cell damage also leads to the production of an abnormal extracellular matrix, which alters retinal pigment epithelium function, and causes choriocapillary loss associated with geographic atrophy ([@b89-cia-3-473]). Damaged retinal pigment epithelial cells can promote an inflammatory response that has been implicated in the development of AMD and the development of neovascularization ([@b56-cia-3-473]). Once damaged, these retinal pigment epithelial cells can secrete growth factors, such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and transforming growth factor beta (TGF-β). These cytokines play a major role in the formation of choroidal neovascularization in AMD ([@b52-cia-3-473]). Recent evidence suggests that within the eye, there is a fine balance between endogenous angiogenic and anti-angiogenic growth factors. Imbalances between these factors can lead to choroidal neovascularization ([@b3-cia-3-473]). VEGF has been found to be one of the key angiogenic growth factors. The family of VEGF proteins, including VEGF-A, VEGF-B, VEGF-C, VEGF-D, and PlGF, exert their function through tyrosine kinase receptors ([@b1-cia-3-473]). VEGF has been shown to be present in choroidal neovascularization membranes ([@b60-cia-3-473]). Conversely, pigment epithelium derived factor (PEDF) is a potent endogenous anti-angiogenic growth factor. PEDF has been shown to significantly suppress VEGF-induced proliferation and migration of vascular endothelial cells ([@b3-cia-3-473]). Decreased PEDF levels have been reported in the vitreous samples of exudative AMD patients ([@b38-cia-3-473]). Choroidal PEDF immunoreactivity is also reduced in AMD patients compared to age-matched controls ([@b3-cia-3-473]). Currently, medications targeting VEGF, such as bevacizumab and ranibizumab, are widely used in the treatment of neovascular AMD. Future therapies may involve anti-angiogenic growth factors, such as PEDF.

Various other proteins can also influence the pathogenesis of AMD. One such molecule, ubiquitin, is an intracellular protein that regulates numerous cellular processes, such as cell-cycle progression, signal transduction, transcriptional regulation, and endocytosis ([@b39-cia-3-473]). It has been implicated in immune responses and apoptosis ([@b39-cia-3-473]). Ubiquitin is prominent in ganglion cells, retinal pigment epithelium and age-related subretinal pigment epithelium deposits ([@b75-cia-3-473]). The ubiquitin pathway involves two steps. The first phase is ubiquitination whereby a substance that needs to be degraded is tagged with specific amino acid sequences. Subsequently, tagged molecules undergo proteolytic degradation through ubiquitin processing enzymes. This process allows damaged or obsolete proteins to be degraded before they aggregate within the cytoplasm. Over time, this protective pathway becomes compromised ([@b75-cia-3-473]). Additionally, hydrogen peroxide (H~2~O~2~) increases the level of oxidized glutathione, which further interferes with ubiquitination ([@b75-cia-3-473]). Ubiquitin, without the active ubiquitin processing enzymes, is found in subretinal pigment epithelial deposits ([@b75-cia-3-473]). It is speculated that with age, ubiquitinated proteins in retinal pigment epithelial cells do not undergo degradation by the ubiquitin processing enzymes ([@b75-cia-3-473]). Therefore, changes in the ubiquitin pathway compromise protein degradation and contribute to subretinal pigment epithelial protein accumulation, which occurs in both advanced age and AMD.

Drusen are subretinal pigment epithelium deposits that are the clinical hallmark of AMD ([@b76-cia-3-473]). There are two classifications of drusen, depending on where they are located: basal linear and basal laminar deposits. Basal linear deposits accumulate between the basal lamina of the retinal pigment epithelium and the inner collagenous zone of Bruch's membrane ([@b76-cia-3-473]). Basal laminar deposits are found between the basement membrane and plasma membrane of the retinal pigment epithelium and consist of basement membrane proteins and collagen. The thickness of drusen deposits have been shown to correlate with the degree of retinal pigment epithelium degeneration, photoreceptor fallout, and vision loss ([@b72-cia-3-473]). Drusen size, number, and degree of confluence are significant risk factors for the development of AMD ([@b7-cia-3-473]). Soft and confluent drusen are a classic clinical hallmark of AMD. Interestingly, the molecular composition of drusen and the atherosclerotic deposits within blood vessels share many similarities ([@b76-cia-3-473]). Both contain vitronectin (a multifunctional plasma and extracellular matrix protein), apolipoprotein E, complement components and lipids ([@b57-cia-3-473]). Nevertheless, a proteonomic analysis comparing drusen in AMD patients and age-matched controls found that although two-thirds of the proteins were similar between the two groups, one-third of the proteins detected in drusen from AMD patients were not found in controls ([@b14-cia-3-473]). Furthermore, it is postulated that the development of drusen is most likely a selective and active process than a passive accumulation of proteins and lipids ([@b14-cia-3-473]). Therefore, drusen formation may be influenced by an individual's genetic predisposition or environmental stressors, which helps explain why all aged patients do not develop AMD ([Figure 2](#f2-cia-3-473){ref-type="fig"}).

With age, drusen can further accumulate on either side of the elastin layer in Bruch's membrane ([@b20-cia-3-473]). Bruch's membrane is a connective tissue layer that lies between the metabolically active retinal pigment epithelial cells and the choriocapillaris. It supplies nutrition to retinal pigment epithelial cells ([@b76-cia-3-473]) and regulates ionic and metabolic exchange between the retinal pigment epithelium and choriocapillaries ([@b64-cia-3-473]). With age, Bruch's membrane increases in thickness from 2 μm in the first decade of life to 4.7 μm in the 10th decade ([@b64-cia-3-473]). Thickened Bruch's membrane can predispose itself to crack formation ([@b12-cia-3-473]). In patients with exudative AMD, Bruch's membrane is more calcified and fragmented than in age-matched controls or patients with nonexudative AMD. These cracks can facilitate the development of choroidal neovascular membranes thus transforming nonexudative to exudative AMD ([@b78-cia-3-473]).

The increased thickness of Bruch's membrane involves both the elastin and collagenous layers and results from decreased degradation and increased production of the extracellular matrix ([@b89-cia-3-473]). Matrix mellatoproteinases (MMPs), which play a role in the degradation of extracellular matrix, and the tissue inhibitors of metalloproteinase (TIMPs), which regulate the activity of MMPs, have been found to change with age ([@b89-cia-3-473]). Increased content of the inactive form of MMP-2, MMP-9 as well as TIMP-3 have been found in the Bruch's membrane of aged patients ([@b89-cia-3-473]). Additionally, MMPs can facilitate choroidal neovascularization. Activated by VEGF, MMPs break down the extracellular matrix, allowing the growth of new vessels ([@b79-cia-3-473]). MMP-2 and MMP-9 have been localized to areas of new vessel development and to the enveloping Bruch's-like membrane suggesting that these enzymes may be cooperatively involved in the progressive growth of choroidal neovascular membranes in AMD. Nevertheless, the amounts of noncollagen proteins, lipid deposits, heparin sulfate, laminin, and fibronectin are also increased in Bruch's membrane with age ([@b89-cia-3-473]). Additionally, glycosaminoglycans increase in size and advanced glycation end products accumulate within Bruch's membrane over time ([@b89-cia-3-473]). The accumulation of cholesterol esters in Bruch's membrane with advancing age is similar to that observed in the arterial intima in atherosclerosis ([@b15-cia-3-473]). This increase in lipid content creates a hydrophobic environment, which changes the flux of solutes and fluids across Bruch's membrane ([@b4-cia-3-473]). Therefore, changes in thickness, molecular composition and electric charge leads to an age-related loss of permeability in Bruch's membrane and alters the movement of nutritional factors from the choriocapillaries toward the retinal pigment epithelial layer and subretinal space, thereby affecting the available nutrients for the outer retina ([@b89-cia-3-473]).

Ocular blood flow changes with age
==================================

There is a progressive decrease in the thickness of the choroid from 193 μm in the first decade of life to 84 μm in the 10th decade ([@b64-cia-3-473]). There is also a 45% decrease in choriocapillary density and a 34% decrease in the lumen diameter of the choriocapillaries with advancing age ([@b64-cia-3-473]). Reduced numbers of macular arterioles and decreased intensity of dye in the macular region have been demonstrated over time using indocyanine green angiography ([@b59-cia-3-473]). These age-related changes were noted only in the arteries, but not in veins. Furthermore, choroidal blood flow changes have been reported with advancing age ([@b64-cia-3-473]). Pulsatile ocular blood flow reflects the total pulsatile component of ocular blood flow and since most of the ocular blood volume is present in the choroid, it mainly represents the choroidal circulation ([@b70-cia-3-473]). [@b65-cia-3-473] and [@b50-cia-3-473] both found a decline in the pulsatile ocular blood flow with age. Animal models have shown a 35%--42% reduction in ocular blood flow and a 57%--93% increase in ocular vascular resistance in aged rats compared with juvenile or adult rats ([@b68-cia-3-473]). Age-related changes in the reflexive choroidal vasodilatation following hypoperfusion have also been shown in rat models ([@b23-cia-3-473]). Neurogenic choroidal blood flow control declines with age both in human and in animal studies ([@b23-cia-3-473]). With the use of laser Doppler flowmetry, [@b33-cia-3-473] reported age-related decreases in choroidal blood flow in the fovea, which was related to decreases in blood volume but not velocity.

The use of color Doppler imaging provides measurements of the retrobulbar vasculature, namely the ophthalmic, central retinal and short posterior ciliary arteries. Retrobulbar changes have been demonstrated with advancing age. Age-related decreases in peak systolic velocity and end-diastolic velocity of the ophthalmic artery have been reported ([@b35-cia-3-473]; [@b50-cia-3-473]). Additionally, Pourcelot's resistive index was increased in the ophthalmic artery ([@b35-cia-3-473], [@b50-cia-3-473]). [@b32-cia-3-473] found a decrease in central retinal artery blood flow by approximately 6%--11% per decade with an increase in the resistive index. On the other hand, [@b35-cia-3-473] found that central retinal artery flow velocity was unaffected by age in both sexes. Nevertheless, they did find that end-diastolic velocity of the posterior ciliary arteries decreased and the resistive index increased with age in women, but not in men.

The perfusion of the optic nerve head is also altered with increasing age. [@b5-cia-3-473] used laser Doppler flowmetry to find that volume and flow in the optic nerve decreased with age, suggesting that blood supply is reduced in elderly subjects. Neuroretinal rim and lamina cribrosa blood flow also decreases with advancing age (Embelton et al 2002). Additionally, [@b66-cia-3-473] used a laser Doppler technique to demonstrate that advancing age is associated with a reduction in capillary red blood cell speed at the optic nerve head.

Ocular blood flow changes in AMD
================================

Atherosclerosis has been postulated to be associated with late stages of AMD through its effect on the choroidal circulation and possible deposition of lipids in the Bruch's membrane ([@b27-cia-3-473]; [@b15-cia-3-473]). A history of cardiovascular disease and increased levels of cholesterol and stage 2 hypertension are strongly associated with neovascular AMD (Hogg et al 2008). The Rotterdam Eye Study demonstrated that persons with subclinical cardiovascular disease, as manifested by carotid artery plaques, were nearly five times more likely to have late AMD compared to patients without such plaques ([@b85-cia-3-473]). The Multiethnic Study of Atherosclerosis (MESA) found an association between the severity of the intima-media thickness of the carotid artery and early AMD in black participants ([@b48-cia-3-473]). Nevertheless, they did not find an association between severity of subclinical atherosclerosis and early AMD in the entire MESA cohort ([@b48-cia-3-473]). The Women's Health Initiative Sight Exam Ancillary Study (WHISE) further reported a positive association between elevated systolic blood pressure and the presence of soft drusen, which correlated inversely with retinal pigment epithelial depigmentation and exudative AMD ([@b49-cia-3-473]). Diastolic blood pressures and mean arterial blood pressures positively correlated with an increased risk of early AMD even after controlling for age ([@b49-cia-3-473]). Although the relationship between blood pressure and AMD is not always consistent, several studies have demonstrated an association. In the Beaver Dam Eye Study, persons with hypertension at baseline were approximately two to three times more likely to develop neovascular macular degeneration after 10 years of follow-up than age-matched controls ([@b46-cia-3-473]). Furthermore, the Age-Related Macular Degeneration Risk Factor Study reported hypertension and high cholesterol to be associated with increased risk of neovascular AMD ([@b41-cia-3-473]).

Since the choriocapillaris supplies the retinal pigment epithelial cells and the outer retina, a primary perfusion defect in the choriocapillaries could lead to loss or dysfunction of retinal pigment epithelial cells ([@b12-cia-3-473]). [@b77-cia-3-473] found increased total luminal area of peripheral choroidal vessels and decreased density of choroidal vessels in the macular area of eyes with AMD. In his theory on the development of AMD, [@b26-cia-3-473] hypothesized that with age, lipoid infiltration occurs within the sclera, Bruch's membrane and the wall of blood vessels, which leads to a decrease in the scleral and choroidal vessels compliance. This decrease in compliance can increase the resistance of the choroidal blood vessels and decrease choroidal perfusion ([@b26-cia-3-473]). The elevated resistance can also increase intravascular pressure and raise hydrostatic pressure. Furthermore, scleral rigidity has been shown to increase with age ([@b50-cia-3-473]; [@b61-cia-3-473]) and in patients with AMD ([@b24-cia-3-473]). All of these changes in the choriocapillaris can impair the retinal pigment epithelial cell transport, promote increased debris accumulation and cause dysfunction of the retinal pigment epithelial cells ([@b26-cia-3-473]) to set the stage for AMD development.

Blood flow analysis in patients with AMD shows decreased choroidal blood flow, velocity and volume in the fovea in AMD patients ([@b34-cia-3-473]). In addition, the severity of AMD increases in patients with the lowest circulatory parameters, possibly contributing to the ischemia and preceding the development of choroidal neovascularization ([@b34-cia-3-473]). With the use of the laser Doppler flowmetry, [@b53-cia-3-473] further investigated choroidal blood flow in the fovea of patients with early AMD with or without systemic hypertension. AMD patients with systemic hypertension had 16.7% lower blood flow compared to patients without hypertension ([@b53-cia-3-473]). These results further suggest that systemic hypertension may contribute to the progression of AMD and the development of choroidal neovascularization ([@b53-cia-3-473]). [@b71-cia-3-473] also used the laser Doppler flowmetry to find that the pulsatility index, pulsatility ratio and resistive index were higher in patients with AMD and increased with disease severity. They found no difference between the mean blood velocity and flow rates and no differences in arterial diameter, suggesting that patients with AMD suffer from decreased compliance in the arterial vasculature ([@b71-cia-3-473]). Pulsatile ocular blood flow has been found to be decreased in exudative AMD compared to nonexudative AMD or normal subjects ([@b55-cia-3-473]). [@b10-cia-3-473] found that the pulsatile ocular blood flow in eyes with drusen was lower than in eyes with choroidal neovascularization and higher in eyes with disciform scar, implying that hemodynamic changes can be partly responsible for asymmetry in some AMD patients. Nevertheless, a recent study of Caucasian patients by [@b70-cia-3-473] demonstrated no differences between the pulsatile ocular blood flow in asymmetric eyes of patients with AMD. Moreover, delayed choroidal filling time has been found in patients with dry AMD ([@b13-cia-3-473]). Prolonged choroidal filling phase was observed in 26% of eyes with early AMD using fluorescein angiography and in 32% of eyes using indocyanine green ([@b63-cia-3-473]). This prolonged filling was also associated with confluent drusen and geographic atrophy in the fellow eye ([@b63-cia-3-473]). Presence of macular watershed zones was also correlated with AMD and one study found that choroidal neovascularization arose from the macular watershed zone in 91% of cases ([@b67-cia-3-473]).

Changes in the retrobulbar blood flow can provide a better understanding of the primary or secondary role of decreased blood flow in AMD. In an animal model, selective damage to retinal pigment epithelial cells caused degenerative changes to the choriocapillaris, suggesting that degeneration of choriocapillaries in AMD can be secondary to dysfunction of the retinal pigment epithelial cells ([@b36-cia-3-473]; [@b17-cia-3-473]). Therefore, secondary damage by retinal pigment epithelium is more likely to affect local blood vessels like the short posterior ciliary arteries and choriocapillaris than the ophthalmic or central retinal arteries. Changes in these vessels can support a more primary role of decrease in blood flow in the development of AMD, although a secondary autoregulatory response to a primary change elsewhere can not be ruled out ([@b11-cia-3-473]). [@b25-cia-3-473] reported that there is elevated pulsatility within all vessels including the ophthalmic, central retinal, and short posterior ciliary arteries, which can indicate an increase in the resistive index. [@b40-cia-3-473] reported that patients with AMD have lower blood velocity and higher resistive index in all retrobulbar vessels including the ophthalmic artery. Studies have found that blood flow velocity was lower in the ophthalmic artery and short posterior ciliary arteries of eyes with choroidal neovascularization compared with eyes without choroidal neovascularization ([@b84-cia-3-473]; [@b11-cia-3-473]). Various studies have reported decreases in the velocity of the short posterior ciliary arteries in AMD patients ([@b25-cia-3-473]; [@b18-cia-3-473]). [@b11-cia-3-473] also found a decrease in the end-diastolic velocity and an increase in the resistive index of the central retinal artery. There are a couple of hypotheses for this change in the central retinal artery blood flow velocity. First, reductions in central retinal artery blood flow may be due to global decreases in retrobulbar blood flow from the ophthalmic artery and its branches. Secondly, decreased retinal blood flow may be related to retinal angiomatous proliferation. [@b87-cia-3-473] described retinal angiomatous proliferation as a phenomenon which occurs in a subgroup of neovascular AMD patients, where angiomatous proliferation originates from the retina and extends posteriorly into the subretinal space, occasionally communicating with choroidal new vessels. Increased flow through new choroidal vessels could decrease flow in the retina and the central retinal artery. Nevertheless, further studies are necessary to determine whether primary or secondary vascular changes play a role in AMD.

Although the hemodynamic abnormalities do not directly indicate that the vascular abnormalities precede the development of AMD, they certainly suggest that hemodynamic changes play an important role in AMD pathogenesis. [@b26-cia-3-473], [@b28-cia-3-473]) uses vascular theory to help explain what is known about the AMD pathophysiology. With advancing age, there is vascular stiffening and increased resistance. As overall vascular resistance increases, cerebral vascular resistance rises and leads to decreased choroidal perfusion and increased osmotic gradients against which retinal pigment epithelial cells must pump. This leads to accumulation of debris in the form of drusen. Furthermore, high choriocapillary pressure in the presence of calcification and fracture of Bruch's membrane and ischemic damage to retinal pigment epithelial cells can cause the secretion of vascular growth factors leading to the development of choroidal neovascularization ([@b26-cia-3-473], [@b28-cia-3-473]). Although this theory has not been confirmed and does not elucidate the differences between races, it provides a well-rounded description of vascular alterations and how they contribute to the pathogenesis of AMD.

Role of genetics in AMD
=======================

Numerous population-based studies have reported differences in prevalence and incidence of AMD between various ethnic/racial groups ([@b45-cia-3-473], [@b47-cia-3-473]; [@b54-cia-3-473]; [@b86-cia-3-473]). Several studies have demonstrated an increased incidence of AMD within families to provide further support for the role of genetics in AMD ([@b73-cia-3-473]; [@b43-cia-3-473]; [@b31-cia-3-473]). Therefore, it is important for investigators to continue to explore the role of genetics and environment on the development of AMD. Although genetic predisposition combined with environmental stressors seem to lead to disease development ([@b81-cia-3-473]), various studies have identified chromosomal abnormalities associated with AMD. Some of the chromosomal regions associated with AMD include 1q31--32, 6q21 and 10q26 ([@b29-cia-3-473]; [@b81-cia-3-473]). Within chromosome segment 10q26, specific gene regions include PLEKHA1, LOC387715 and HTRA1 ([@b81-cia-3-473]). Complement factor H, within chromosomal segment 1q31--32, is a key regulator in the alternative complement cascade and prevents uncontrolled complement activation ([@b88-cia-3-473]). [@b82-cia-3-473] performed a meta-analysis between complement factor H Y402H polymorphism and AMD to find that heterozygotes (TC) and homozygotes (CC) were, respectively, 2.5 and 6 times more likely to have AMD than homozygote patients with the TT genotype. Nevertheless, a Japanese study found that this complement factor H gene did not appear to increase risk of AMD within their population ([@b30-cia-3-473]). This appears to demonstrate that there are differences amongst various ethnic groups. Furthermore, within chromosome 6q21, polymorphisms of complement factor B and complement component 2 have been shown to be a risk predictor of AMD ([@b29-cia-3-473]). These correlations between complement-related genes and AMD further support the role of the inflammatory system in the development of AMD. In addition, a previous study by [@b57-cia-3-473] found that drusen can contain activated complement factors, acute phase reactants, coagulation proteins, immunoglobulins, and other proteins involved in the induction and activation of the immune response.

Not only can an individual's genetic predisposition influence the development of AMD, but it is also associated with the rate of disease progression. [@b74-cia-3-473] analyzed patients from the Age-Related Eye Disease Study (AREDS) to determine whether variations within the complement factor H gene and the LOC387715 gene have prognostic importance in AMD disease progression. Although genetic polymorphisms in the complement factor H Y402H and LOC387715 A69S were associated with progression to more advanced AMD, the LOC387715 genotype was also correlated with neovascular disease more than geographic atrophy. Patients who were homozygous for the risk alleles had a nearly 50% probability for AMD progression compared to the 5% risk in patients who are homozygous for the nonrisk alleles ([@b74-cia-3-473]). Additionally, presence of the homozygous risk alleles combined with smoking and high body mass indices were associated with 19-fold increase of disease progression ([@b74-cia-3-473]). Conversely, some genetic variations have been found to play a protective role in AMD development and progression. Apolipoprotein E is involved in transport and metabolism of lipid and cholesterol and in response to neural injury ([@b81-cia-3-473]). The ɛ4 allele of apolipoprotein E has been associated with the reduced prevalence of AMD. There is strong evidence for the role of genetics in AMD, but further research is necessary to determine how genetic differences can ultimately lead to AMD.

Conclusion
==========

Several systemic and ocular diseases increase in incidence and prevalence in the elderly population. Although AMD development shares many correlations with normal aging processes, other factors, such as genetic predisposition or environmental stressors, may account for disease development ([Figure 2](#f2-cia-3-473){ref-type="fig"}). Furthermore, the similarities between drusen and atherosclerosis demonstrate that a vascular component may play a role in AMD development. Apart from the structural changes, age-related alterations in ocular hemodynamics can precede and correlate with the AMD pathogenesis, which further supports the vascular theory of AMD.

Although aging alone is not sufficient to form AMD, it is apparent that the age-related changes and genetics are very important to the pathophysiology of AMD. Understanding the processes that develop with age and in age-related diseases can help guide new early treatment modalities. Further studies are warranted in order to learn how age-associated vascular and ocular structural changes lead to disease development. This will help generate the knowledge needed to identify target areas that may be useful to prevent disease progression through medical or surgical treatment.
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![An illustration of the late form of AMD, showing the growth of the choroidal neovascularization from the choroicapillaris through the Bruch's membrane into the subretinal space. These new vessels are abnormal and have a higher tendency of leakage and bleeding. Reprinted with permission from [@b6-cia-3-473]. Age-related macular degeneration. *Surv Ophthalmol*, 32:375--413. © 1998 Elsevier.](cia-3-473f1){#f1-cia-3-473}

![The vascular and nonvascular theory of AMD. The vascular theory, suggested by [@b26-cia-3-473], states that with increased resistance in the choroidal vessels, there is an increase in the osmotic gradient against which the retinal pigment epithelial cells must pump. This leads to retinal pigment epithelial cell dysfunction and the accumulation of metabolic debris and drusen formation. Furthermore, the decrease in choroidal perfusion causes ischemic/hypoxic injury and increased oxidative stress, which can signal choroidal neovascularization formation. On the other hand, in the nonvascular theory, senescent retinal pigment epithelial cells can lead to retinal pigment epithelial cell dysfunction, which in turn can cause choriocapillary atrophy. Over time, and individual's genetic predisposition and environmental stressors in the setting of structural and vascular changes make the eye more susceptible to AMD development.](cia-3-473f2){#f2-cia-3-473}
